Business · 08/12/2010
FDA Requests Stakeholder Input on Biosimilar User Fee Program
The FDA is seeking public input from patient groups, healthcare professionals, and experts on a user fee program for biosimilar and interchangeable biological products, as required by the Patient Protection and Affordable Care Act.
Original source language: Federal Register — Health and Human ServicesOpen original release →